Mutation-resistant nano therapeutics inhibiting infection progress of RNA-virus, SARS-CoV-2

ACELLMED Sp. z o.o., the Silesian Medical Technology Park Kardio-Med Silesia and the University of Wrocław – Faculty of Biotechnology, have established cooperation for the implementation of a project co-financed by the Medical Research Agency under the “Call for proposals for the development of innovative therapeutic solutions using RNA technology.”  under the call ABM/2021/5.

The project is named: “Mutation-resistant nano therapeutics inhibiting infection progress of RNA-virus, SARS-CoV-2.”

PROJECT OBJECTIVE – development of R&D activity and competitiveness through implementation of R&D works, which will result in a drug inhibiting leukemia cell proliferation used during oncology therapy. The goal will be achieved by October 2025.

The main scientific objective is to develop an effective therapy for Sars-CoV-2 infection. Acellmed, the Silesian Medical Technology Park Kardio-Med Silesia and the University of Wroclaw aim to develop a drug that can be used to treat the progression of COVID-19 disease.

Project objectives:

Project implementation period: 01.09.2021-31.10.2025

Project value:

 



    This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

    I consent to the processing of my personal data by Śląski Park Technologii Medycznych Kardio-Med Silesia Sp. z o.o., 10C M. Curie-Skłodowskiej St., 41-800 Zabrze, KRS:0000396540, NIP:6482761515, Regon:242742607, as Data Controler in order to receive a response. I can withdraw my consent by submitting a statement to: iod@kmptm.pl. The Data Controler has notified me that this consent does not affect the legality of the processing carried out on the basis of consent before its withdrawal.

    The information clause on the details of the processing is available here.

    Supporting partners:

    Partners: